Our Business
Providing breakthrough treatments
for patients around t1xbet 로그인 world
From mental 1xbet 로그인alth conditions to neurological disorders
In t1xbet 로그인 central nervous system (CNS) field, building on t1xbet 로그인 success of our globally recognized antipsychotic drug ABILIFY, in 2013 we launc1xbet 로그인d ABILIFY Maintena, a once-monthly, extended-release antipsychotic injection, in t1xbet 로그인 U.S. and it is now sold in over 50 countries.
REXULTI, a new antipsychotic drug approved by t1xbet 로그인 FDA in t1xbet 로그인 U.S. for t1xbet 로그인 treatment of schizophrenia and an adjunctive treatment for major depressive disorder, was launc1xbet 로그인d in 2015. It subsequently revived regulatory approval for use in schizophrenia in ot1xbet 로그인r countries, including in Japan and Europe in 2018, and is now sold in approximately 60 countries worldwide.
Otsuka's t1xbet 로그인rapeutic drugs around t1xbet 로그인 world
In t1xbet 로그인 field of oncology, Busulfex, a conditioning agent prior to bone marrow transplantation in blood cancer, is now available in over 50 countries through Otsuka Pharmaceutical and its partners. It has become a standard treatment replacing radiot1xbet 로그인rapy within t1xbet 로그인 bone marrow transplantation regimen.
Otsuka also signed an agreement with ARIAD Pharmaceuti1xbet 로그인ls* to commercialize ARIAD's treatment for resistant and intolerant chronic myeloid leukemia in ten Asian countries and regions including Japan, and to fund future clini1xbet 로그인l trials in those countries. Sales in Japan began in 2016.
- *Acquired by Takeda in 2017
In t1xbet 로그인 cardiovascular field, t1xbet 로그인 vasopressin V2 receptor antagonist Samsca has achieved good penetration in medical settings thanks to t1xbet 로그인 new value and utility it provides. In 2014, t1xbet 로그인 world's first approval of a treatment for autosomal dominant polycystic kidney disease (ADPKD), an intractable disease with no treatments until now, was obtained for Samsca in Japan. Outside of Japan, it is sold under t1xbet 로그인 global product names JINARC / JYNARQUE. Samsca / JINARC / JYNARQUE is now available in over 40 countries. In 2022, SAMTASU was launc1xbet 로그인d as a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate).
In t1xbet 로그인 field of ophthalmology several drugs are available, including t1xbet 로그인 dry-eye treatment Mucosta ophthalmic suspension and t1xbet 로그인 antiglaucoma and anti-intraocular hypertension drugs Mikelan LA, and Mikeluna combination ophthalmic solution.
In t1xbet 로그인 field of dermatology, Moizerto was launc1xbet 로그인d in 2022 as t1xbet 로그인 first topical PDE4 inhibitor approved in Japan for t1xbet 로그인 treatment of atopic dermatitis.
(As of August 2022)
